However, a transient CD4 decline to <350 cells/mm3 among virologically suppressed patients is common [2], [14] and, given the low incidence of Hodgkin lymphoma among HIV-infected patients in Northern Europe, it is possible that a transient decline in CD4 count may trigger clinicians to undertake unnecessary investigations and follow up. The gene discussed is CD4; the disease is Hodgkins lymphoma.